Business
Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA®
Scilex launched its third commercial product, GLOPERBA® on June 10, 2024.Scilex has officially shipped its recently approved, GLOPERBA® to many national
About this update from Scilex Holding Company
[{"type":"text","content":"Scilex launched its third commercial product, GLOPERBA® on June 10, 2024.Scilex has officially shipped its recently approved, GLOPERBA® to many national drug/pharmacy chains, as well as independent pharmacies.GLOPERBA® will be the first oral liquid medicine for prophylaxis of gout flares available beginning this week with a WAC Price of $595/bottle.Scilex is also in the process of negotiating similar potential stocking arrangements with additional pharmacy chains in the U.S.Scilex remains committed to ensuring broad access, awareness and strong supply for broad distribution efforts across the U.S.Gout is a painful arthritic disorder affecting an estimated 9.2 million people in the United States1. As gout cases increase every year, treatment requirements increase. The gout treatment market is projected to be $2.0 billion in the U.S. by 2028 with a well-defined area of unmet need.2 PALO ALTO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that many national pharmacy chains and independent pharmacy stores have begun stocking GLOPERBA®. Scilex launched GLOPERBA®, an FDA-approved prophylactic treatment for painful gout flares in adults in the U.S., on June 10, 2024. For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com. About Scilex Holding Company Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved,...